Tumor associated antigens combined with carbon dots for inducing durable antitumor immunity.
J Colloid Interface Sci
; 673: 594-606, 2024 Nov.
Article
in En
| MEDLINE
| ID: mdl-38897061
ABSTRACT
Although therapeutic nanovaccines have made a mark in cancer immunotherapy, the shortcomings such as poor homing ability of lymph nodes (LNs), low antigen presentation efficiency and low antitumor efficacy have hindered their clinical transformation. Accordingly, we prepared advanced nanovaccines (CMB and CMC) by integrating carbon dots (CDs) with tumor-associated antigens (B16F10 and CT26). These nanovaccines could forwardly target tumors harbouring LNs, induce strong immunogenicity for activating cytotoxic T cells (CTLs), thereby readily eliminating tumor cells and suppressing primary/distal tumor growth. This work provides a promising therapeutic vaccination strategy to enhance cancer immunotherapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carbon
/
Cancer Vaccines
/
Quantum Dots
/
Antigens, Neoplasm
Limits:
Animals
Language:
En
Journal:
J Colloid Interface Sci
Year:
2024
Document type:
Article
Country of publication:
United States